Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Overall alignment is partial: several statements about hepatic adverse effects and nonspecific monitoring are consistent with the provided label excerpts, but the response adds elderly-specific monitoring signs (jaundice, fatigue) not supported by the provided labeling text.
Category Scores
Accurate Statements
Increased liver enzyme levels can be a sign of liver damage.
Supported by Section 5.4 describing increases in transaminases and abnormal liver function tests with monitoring for worsening hepatic function.
Clinicians should carefully monitor elderly patients for signs of liver toxicity such as elevated liver enzymes ... during tigecycline treatment.
Partially supported: Section 5.4 supports monitoring patients who develop abnormal liver function tests; 'elevated liver enzymes' is consistent with transaminase/LFT monitoring, but the claim is framed specifically for elderly and adds other signs not in the excerpt.
Patients who develop abnormal liver function tests during tigecycline therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline.
Section 5.4 (as reflected in the response’s overall management/monitoring theme).
Unsupported Statements
Clinical trials and observational studies report that elderly patients have increased levels of liver enzymes during tigecycline treatment.
Not supported by the provided excerpts (Section 8.5 does not provide age-stratified hepatic enzyme findings; Section 5.4 does not describe elderly-specific enzyme increases).
Age-related changes can reduce the liver's efficiency at metabolizing drugs, which can lead to increased drug levels and increased risk of toxicity for tigecycline.
Mechanistic explanation about metabolism/drug levels is not present in the provided excerpts (only general sensitivity in some older individuals cannot be ruled out).
Elderly patients often have comorbidities such as diabetes, hypertension, and kidney disease, which can interact with tigecycline and increase the risk of liver toxicity.
Comorbidities and specific interactions are not identified in the provided excerpts.
Elderly patients are more likely to take multiple medications (polypharmacy), including other drugs that can interact with tigecycline and increase the risk of liver toxicity.
While Section 5.4 notes some patients with significant hepatic dysfunction were receiving multiple concomitant medications, the claim that elderly patients are more likely to have polypharmacy is not supported by the provided excerpts.
Contradictions
Important Omissions
Label-congruent monitoring guidance: evaluate risk/benefit of continuing tigecycline and note that hepatic dysfunction may occur after discontinuation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The main risk comes from adding specific elderly monitoring targets (jaundice, fatigue) not supported by the provided label excerpts; while this may not be directly harmful, it is a misalignment that could lead to inaccurate or overconfident clinical expectations relative to the label wording. Other major dose-management recommendations (dose reduction/switching antibiotics) were not supported but were also not directly supported by the label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Adds elderly-specific hepatic toxicity monitoring signs (jaundice, fatigue) and several mechanistic/comorbidity/polypharmacy assertions not supported by the provided label excerpts.
Suggested Improvement
Limit statements to the provided label language: hepatic adverse effects include increases in bilirubin/prothrombin time/transaminases; monitor patients with abnormal liver function tests for worsening hepatic function and evaluate risk/benefit of continuing tigecycline. For geriatric use, use the label’s wording that no overall safety/effectiveness differences were observed but greater sensitivity in some older individuals cannot be ruled out; avoid age-stratified enzyme claims, mechanistic metabolism assertions, or specific comorbidity/polypharmacy details unless present in the provided label text.